U.S. pharmacy groups applaud journalists’ deep dive into the practices of pharmacy benefits managers that increase drug costs, reduce pharmacy sustainability.
The lawsuit alleges that companies benefitted from the opioid crisis ‘by negotiating favorable deals with opioid manufacturers and by not taking sufficient action to curb excessive opioid prescriptions.
Attorney General Niki Sharma says the province is the first Canadian jurisdiction to sue makers of perfluoroalkyl and polyfluoroalkyl substances, known as PFAS chemicals.
The prices charged by Ontario company Canadian Health Labs under its contract with Vitalité were described as exorbitant by Health Minister Bruce Fitch.
In its appeal, the AQPP denounces an ‘opaque ecosystem for the distribution of specialty drugs’ which would harm the financial health of community pharmacies and patient safety.
Pharmacy staffers are encouraged to call and report corporate pressures that impact their well-being or interfere with their ability to deliver patient care.
